Hikma Pharmaceuticals PLC
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HKMPF research report →
About the company
Hikma Pharmaceuticals PLC is a global pharmaceutical firm engaged in the development, manufacturing, commercialization, and distribution of a wide array of medications, including its own branded products, licensed drugs, and generic formulations. These pharmaceutical offerings come in various forms, such as solids, semi-solids, liquids, and injectables. The company's operations are divided into three core segments: Injectables, which primarily supplies generic injectable medications to hospitals; Generics, focusing on oral and other non-injectable generic drugs for the retail market; and Branded, which provides both proprietary generics and in-licensed pharmaceuticals to retail consumers and healthcare institutions.
- CEO
- Said Samih Taleb Darwazah
- IPO
- 2012
- Employees
- 9,500
- HQ
- London, GB
Price Chart
- Market Cap
- $4.23B
- P/E
- 0.19
- P/S
- 1.30
- P/B
- 1.75
- EV/EBITDA
- 8.40
- Div Yield
- 3.99%
- Gross Margin
- 41.35%
- Op Margin
- 16.81%
- Net Margin
- 12.00%
- ROE
- 15.83%
- ROIC
- 10.21%
- Revenue
- $3.35B · 7.10%
- Net Income
- $410.94M · 14.47%
- EPS
- $1.86 · 14.81%
- Op Income
- $580.63M
- FCF YoY
- -58.50%
- 52W High
- $27.96
- 52W Low
- $16.34
- 50D MA
- $19.20
- 200D MA
- $20.24
- Beta
- 0.65
- Avg Volume
- 159
Get TickerSpark's AI analysis on HKMPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our HKMPF coverage
Recent articles, reports, and earnings notes.
No research on HKMPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HKMPF report →Similar companies
Peers in the same neighborhood.